You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Predictors for Response or Resistance to Immunotherapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Interleukin 4 and Interferon Gamma Predictors of Human

Completed
  • Warts Hand
  • Wart, Genital
  • IL-4 and IFN-γ measurements
  • Zagazig, Sharkia, Egypt
    Zagazig University Faculty of Medicine
Oct 28, 2021

Hepatocellular Carcinoma Non-resectable Trial in Honolulu (Fluorine-18 fluorocholine)

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • Fluorine-18 fluorocholine
  • Honolulu, Hawaii
    The Queen's Medical Center
Mar 28, 2022

Cutaneous Melanoma Trial in Paris (Blood sample, Cutaneous melanoma biopsy)

Recruiting
  • Cutaneous Melanoma
  • Blood sample
  • Cutaneous melanoma biopsy
  • Paris, Ile De France, France
    Dermatology department
Oct 24, 2022

Molecular Predictors of Resistance and Response to Regorafenib

Completed
  • Metastatic Colorectal Cancer
  • Carshalton, Surrey, United Kingdom
    The Royal Marsden NHS Foundation Trust London and Surrey
Apr 30, 2021

Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8 Trial

Not yet recruiting
  • Metastatic Nasopharyngeal Carcinoma
  • +2 more
  • Nivolumab
  • +5 more
  • (no location specified)
Aug 21, 2023

Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8 Trial

Not yet recruiting
  • Metastatic Nasopharyngeal Carcinoma
  • +2 more
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Jun 13, 2023

l Science Network of Precision-based Immunotherapy for Primary

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
    • La Jolla, California
    • +6 more
    Jan 24, 2023

    Cancer Patients Trial in Jinan (At the same time, the original regimen of immunomaintenance therapy was continued, according to

    Recruiting
    • Cancer Patients
    • At the same time, the original regimen of immunomaintenance therapy was continued, according to the frequency of the original immunization regimen once every 3 weeks until progress.
    • Jinan, In Shandong Province, China
      The First Affiliated Hospital of Shandong First Medical Universi
    Sep 16, 2022

    Cancer Patients Trial in Jinan (Low-dose radiotherapy combined with conventional fractionated radiotherapy)

    Recruiting
    • Cancer Patients
    • Low-dose radiotherapy combined with conventional fractionated radiotherapy
    • Jinan, In Shandong Province, China
      The First Affiliated Hospital of Shandong First Medical Universi
    Jun 7, 2023

    Advanced Melanoma

    Enrolling by invitation
    • Melanoma
    • observational
    • Durham, North Carolina
      Duke University Medical Center
    Aug 16, 2022

    Colon Cancer, Liver Metastasis Colon Cancer, Rectal Cancer Trial in Ramat Gan (Hepatopulmonary radio-sterilization)

    Not yet recruiting
    • Colon Cancer
    • +2 more
    • Hepatopulmonary radio-sterilization
    • Ramat Gan, Israel
      Sheba Medical Center
    Sep 21, 2023

    Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT

    Recruiting
    • Lung Cancer Stage III
    • Lung Cancer Stage IV
      • Brest, France
        Chu Brest
      Aug 16, 2023

      Metastatic Lung Cancer Trial in Beer sheva, Petah Tikva (Antibiotics, FMT (Fecal Microbiota Transplantation), Placebo

      Not yet recruiting
      • Metastatic Lung Cancer
      • Beer sheva, Israel
      • +1 more
      Aug 14, 2022

      Metastatic Extracranial Malignant Solid Tumor, Radiotherapy, Immune Checkpoint Blockade Trial in Shantou (Intestinal Low Dose

      Not yet recruiting
      • Metastatic Extracranial Malignant Solid Neoplasm
      • +3 more
      • Intestinal Low Dose Radiotherapy-1Gy
      • +3 more
      • Shantou, Guangdong, China
        Cancer Hospital, Shantou University Medical College
      Oct 7, 2023

      Stage IIIB(N2) NSCLC, Stage IIA NSCLC, Stage IIB NSCLC Trial in Beijing (Pembrolizumab 200 mg IV infusion)

      Not yet recruiting
      • Stage IIIB(N2) Non-small Cell Lung Cancer
      • +3 more
      • Pembrolizumab 200 mg IV infusion
      • Beijing, Beijing, China
        Peking University
      May 30, 2023

      Molecular Subtyping of Extensive Stage Small Cell Lung Cancer

      Recruiting
      • SCLC,Extensive Stage
      • PD-(L)1 antibody immunotherapy
      • Beijing, Beijing, China
        Peking University Cancer Hospital & Institute
      Jul 3, 2023

      HCC Trial in Hong Kong (Zabadinostat (CXD101) and Geptanolimab, Lenvatinib and Sorafenib)

      Not yet recruiting
      • HCC
      • Zabadinostat (CXD101) and Geptanolimab
      • Lenvatinib and Sorafenib
      • Hong Kong, Hong Kong
        Department of Clinical Oncology, Prince of Wales Hospital
      May 15, 2023

      Carcinoma, Renal Cell, NSCLC Trial in Belgium, France (Live Bacterial Product - Akkermansia muciniphila)

      Recruiting
      • Carcinoma, Renal Cell
      • Carcinoma, Non-Small-Cell Lung
      • Live Bacterial Product - Akkermansia muciniphila
      • Mons, Belgium
      • +3 more
      May 9, 2023

      Stage II Melanoma Trial in Wollstonecraft (Relatlimab and nivolumab fixed dose combination (FDC))

      Not yet recruiting
      • Stage II Melanoma
      • Relatlimab and nivolumab fixed dose combination (FDC)
      • Wollstonecraft, New South Wales, Australia
        Melanoma Institute Australia
      Oct 26, 2022

      Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin

      Recruiting
      • Gastric Cancer
      • Tianjin, Tianjin, China
        Tianjin Medical University Cancer Institute and Hospital
      Oct 22, 2023

      Response and Resistance to Pembrolizumab in Melanoma

      Recruiting
      • Melanoma
      • Advanced Melanoma
      • Biopsy
      • Biospecimen Collection
      • San Francisco, California
        University of California, San Francisco
      Nov 17, 2022

      Non-Small Cell Bronchopulmonary Carcinoma or Melanoma Trial in Nice (18FDG PET)

      Recruiting
      • Non-Small Cell Bronchopulmonary Carcinoma or Melanoma
      • 18FDG PET
      • Nice, France
        Centre Antoine Lacassagne
      Sep 13, 2022

      Microenvironment of Lung Cancer and Exploration of Mechanism of

      Recruiting
      • Lung Cancer
      • Multiomics analysis
      • Yiwu, Zhejiang, China
        The Fourth Affiliated Hospital of Zhejiang University
      Dec 16, 2022

      Treatment Resistance in Obsessive Compulsive Disorder

      Not yet recruiting
      • OCD
      • Functional MRI
      • (no location specified)
      Apr 25, 2023

      Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma Trial in Australia, United States (Prednisone, Vincristine,

      Recruiting
      • Acute Lymphoblastic Leukemia
      • Acute Lymphoblastic Lymphoma
      • Palo Alto, California
      • +6 more
      May 2, 2022